German Merck KGaA’s recently acquired subsidiary SpringWorks Therapeutics today announced that long-term efficacy and safety data from the Phase III DeFi trial of Ogsiveo (nirogacestat) were in the ...
Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in ...
Merck & Co., Inc. (NYSE:MRK) is included among the 11 Defensive Healthcare Dividend Stocks to Buy Now. Merck & Co., Inc.
SpringWorks Therapeutics Inc. shares SWTX were on track for a record percentage gain on Tuesday after the company got the first U.S. regulatory approval for a drug targeting a rare type of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback